Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced its financial results for the three and six months ended June 30, 2008. For the three months ended June 30, 2008, the Company posted revenues of $4.3 million and a net loss of $7.2 million. For the six months ended June 30, 2008, revenues were $21.3 million and the net loss was $3.5 million. The revenue in the six month period includes $10.8 million of revenue earned in the first quarter attributable to the one-time recognition of an upfront payment related to the Company's collaboration with Novartis. Cash, cash equivalents and short-term investments totaled $23.7 million at June 30, 2008 compared to $39.0 million at December 31, 2007.

Total revenues for the three months ended June 30, 2008 were $4.3 million compared to $8.5 million for the three months ended June 30, 2007. Total revenues for the six months ended June 30, 2008 were $21.3 million, compared to $19.5 million for the six months ended June 30, 2007. The decrease of $4.2 million for the three month period was primarily attributable to a decrease in revenues recognized under our Novartis collaboration due to the conclusion of the research term in late March 2008 and a decrease in revenues earned under our federal research grant. The increase of $1.8 million for the six month period was primarily due to an increase in revenue recognized under the Novartis collaboration, as noted previously, offset by a decrease in revenues from the Company's federal research grant. This decrease was primarily due to the recognition of $3.5 million of revenue during the first quarter of 2007 in connection with an agreement on the reimbursement of overhead costs incurred on grant research efforts
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... Sept. 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), a ... metabolic and cardiovascular diseases, today announced that it,is ... human clinical trial of,plant-produced insulin now that the ... application has passed. SemBioSys submitted,the application in July ...
... of a Phase ... of Seasonal Influenza Vaccine, ROCKVILLE, Md., Sept. 16 ... volunteers in a Phase,II clinical trial of its virus-like particle ... clinical trial will,evaluate the safety and immunogenicity of different doses ...
... Inc. (the,"Company" or "MIGENIX") (TSX: MGI; OTC: ... diseases, reports financial results for the three,months ... corporate update on its programs,and other matters., ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide;,prevention ...
Cached Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11
(Date:10/14/2014)... 2014)—It,s been millions of years since T. rex ... by Ohio University scientists is breathing life back into ... dinosaur snouts. The research has important implications for how ... to enhance the sense of smell and cool their ... Ohio University doctoral student Jason Bourke, lead author of ...
(Date:10/14/2014)... is how to produce enough food to feed the ... Agriculture Organization of the United Nations predicts that food ... to feed a growing global population, and plants are ... production. Plants—grains, cereals, fruits, vegetables, and more—feed humans ... must tap into our knowledge of how plants work ...
(Date:10/14/2014)... fish oil supplements, rich in omega-3 fatty acids, do not ... which the heart can beat as fast as 150 beats ... the Montreal Heart Institute were published in the Journal ... , For the trial, 337 patients with atrial fibrillation not ... of fish oil a day or to placebo for up ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... , , SEATTLE, Dec. 18 Pacific ... a leading provider of specialized central laboratory and contract research ... that were voted upon at the Company,s Annual Meeting on ... approve a change in the Company,s name to "Pacific Biomarkers, ...
... PITTSBURGHResearchers at Carnegie Mellon University,s National Robotics Engineering ... computer vision and machine learning to inspect and grade ... quality tasks that until now could only be ... fall, the machine classified and sorted harvested plants more ...
... 17, 2009 Time and time again, it has been ... risks associated with the comorbidities of obesity. With only ... Institutes of Health exercise guidelines of 300 minutes/week, a study ... Nutrition Education and Behavior explores the paradox that exists ...
Cached Biology News:Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 3Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 4Carnegie Mellon engineers develop machine that visually inspects and sorts strawberry plants 2Negative emotions outweigh intent to exercise at health clubs 2
Syd-2 (cL-19)...
... isolation and affinity purification of small ... Hydrophobic, monodisperse magnetic particles (2.8 m ... further surface activation is not required. ... optimal orientation for affinity purification of ...
ZO-2 (H-110)...
p-Bcl-2 (Thr 74)...
Biology Products: